CDIX
Cardiff Lexington Corporation1.4200
-0.2900-17%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
57.37MP/E (TTM)
-Basic EPS (TTM)
-0.27Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Cardiff Lexington's Q2 FY2025 revenue surged 89.5% y/y to $2.8M, all from its healthcare segment, while gross profit jumped 149.8% to $1.7M with margins expanding to 60.8% from 46.1%, driven by a higher 43.18% settlement realization rate on gross billed charges. Operating income flipped to $610K from a $159K loss, though net loss widened to $1.2M due to $1.8M in interest expense on its line of credit. YTD revenue rose 50.4% to $5.7M with gross margins at 62.0%, but net loss hit $1.7M amid $2.8M interest costs; EPS of -$0.08 reconciles to 18.8M weighted shares. Cash dipped to $560K with negative FCF of $1.9M from operations, offset by $1.5M line draws, leaving $13.1M total debt and $2.3M unused credit; no M&A closed. Competition in orthopedic services remains a key risk.
8-K
Financial restatement announced
Cardiff Lexington's audit committee determined on August 12, 2025, that financial statements in five prior reports—from Q1 2024 to Q1 2025—can't be relied upon due to misclassification of non-cash interest expense in cash flow statements. The errors are purely presentational, leaving total cash, earnings, and debt compliance untouched. Amendments will reclassify the items soon. No impact on operations.
10-Q
Q1 FY2025 results
Cardiff Lexington's Q1 FY2025 revenue climbed 25.6% y/y to $2.9M, all from its healthcare segment, while gross margin expanded to 63.1% from 59.2% thanks to higher patient volumes and complex procedures. Operating income rose sharply to $544K from $219K, but net loss widened to $451K from $283K, driven by interest expense surging to $993K from $376K on heavier line-of-credit draws. Cash dipped to $997K amid $1.6M operating burn, offset by $1.4M in financing; free cash flow not disclosed in the 10-Q. Line of credit hit $10.2M with $4.8M available, total debt $10.7M mostly short-term. No M&A closed this quarter. Yet competition in orthopedic services lingers as a key risk.
10-K
FY2024 results
Cardiff Lexington Corporation's FY2024 results showed revenue declining 30% year-over-year to $8.3 million, driven by Nova Ortho's shift to lower-margin pain management services and Florida's disruptive hurricane season, which shuttered facilities temporarily; yet Q4 signaled momentum with settlement rates rebounding to 49% from a 44% average as accelerated collections eased. Gross margins compressed to 53.6% from 70.0%, reflecting higher surgical costs amid inflation, while operating expenses rose 49% on staffing and legal fees, yielding a $0.2 million operating loss versus $5.2 million profit in FY2023. Liquidity strengthened with $1.2 million cash and a $15 million line of credit, up from $4.5 million, funding $6.5 million draws to offset $5.9 million operating outflows; no dividends or buybacks occurred, but capex remained minimal. No annual guidance was disclosed, though management eyes outpatient surgery center acquisitions. Extended 18-24 month receivables cycles risk cash flow amid litigation uncertainties.
IPO
Website
Employees
Sector
Industry
BKD
Brookdale Senior Living Inc.
10.49+0.19
CAH
Cardinal Health, Inc.
197.89-2.07
EHC
Encompass Health Corporation
108.01+0.42
HCA
HCA Healthcare, Inc.
469.79-7.19
NHC
National HealthCare Corporation
138.93-0.94
NUTX
Nutex Health Inc.
171.72-4.06
PACS
PACS Group, Inc.
34.20-0.55
PIII
P3 Health Partners Inc.
4.59-0.36
SNDA
Sonida Senior Living, Inc.
31.53-0.06
SRXH
SRX Health Solutions, Inc.
0.38+0.07